Aging, acute myelogenous leukemia, and allogeneic transplantation: do they belong in the same sentence?

Abstract

Acute myelogenous leukemia is a disease of the elderly. Disease biology and functional status of this patient population contribute to poorer treatment outcomes with standard therapy. Allogeneic hematopoietic stem cell transplantation is associated with an immunologic "graft-versus-tumor" effect. However, transplantation was restricted until recently to younger patients because of prohibitive treatment-related mortality. The development of reduced-intensity preparative regimens and improvements in supportive care now allow older patients with myeloid leukemia a greater opportunity for cure with transplantation. Donor availability, graft-versus-host disease, delayed immune recovery, and the high prevalence of relapsed or refractory disease remain important obstacles to be overcome in the future. Herein, we review the current literature on transplantation for older patients with this myeloid malignancy.

• Authors: Stefan O Ciurea, Morgani Rodrigues, Sergio Giralt, Marcos de Lima
• Journal: Clinical lymphoma & myeloma (Clin Lymphoma Myeloma) Vol. 9 Issue 4 Pg. 289-97 (Aug 2009) ISSN: 1938-0712 [Electronic] United States
• PMID: 19717378 (Publication Type: Journal Article, Review)

Topics

• Age Distribution
• Aged
• Aging (physiology)
• Hematopoietic Stem Cell Transplantation
• Humans
• Leukemia, Myeloid, Acute (diagnosis, therapy)
• Survival Rate
• Transplantation, Homologous